On the latest edition of Market Week in Review, Director and Senior Investment Strategist Paul Eitelman and Senior Client Investment Analyst Chris Kyle discussed the ongoing volatility in equity markets, recent U.S. inflation data and the latest on a potential vaccine for COVID-19.
Nasdaq enters correction territory as market volatility continues
In the wake of the sharp selloff in equity markets on Sept. 3, the tech sector continued to drag major indices lower the week of Sept. 7, with the Nasdaq Composite Index ending the week down approximately 4%. Since the tech-fueled selloff began, the Nasdaq Composite has dropped 10% – as of mid-morning Pacific time on Sept. 11 – meaning it’s technically in correction territory, Eitelman noted. So, what exactly is behind the market downturn?
“This is a bit of a strange one, as it’s hard to point to a specific event or catalyst behind the selloff,” Eitelman said. “Instead, what seems to be happening is that mega-cap tech stocks are selling off simply because their valuations became a bit overextended.”
Eitelman stated that at this stage, he doesn’t believe there’s reason to be overly concerned about the selloff, as many of the tech companies coming under selling pressure experienced a meteoric rise in valuations over the last few months. Going forward, the performance of big tech names will be an especially important watchpoint for the market, he noted, given that major U.S. equity indices such as the S&P 500® Index have become highly concentrated due to the recent outperformance of the tech sector.
“At Russell Investments, broadly speaking, our equity strategies are set up to potentially benefit from a rotation from tech into the more dislocated and cheap areas of the market – so we’ll be paying close attention,” he said. Ultimately, volatility has become more two-sided lately, Eitelman remarked, characterizing this as healthier for the market overall.
U.S. inflation data suggests no rate hikes anytime soon
The U.S. consumer price index rose slightly more than expected during August, climbing 0.4% on a month-over-month basis, Eitelman said. While the monthly increase was the third straight for the index, which rose 0.6% in both June and July, on a year-over-year basis, core prices increased by just 1.7% – far below the U.S. Federal Reserve (the Fed)’s target of 2%, he noted.
Inflation is likely to remain muted for a while going forward, Eitelman said, as the U.S. continues to slowly crawl its way out of the coronavirus-induced recession. “Higher inflation typically occurs when aggregate demand is so strong that it outpaces the productive capacity of the economy to produce the in-demand goods and services,” he explained. “Right now, aggregate demand is still rather weak.”
The main takeaway from all of this? The Fed will keep interest rates very low for a long time, Eitelman said – especially in light of the central bank’s recently concluded policy review. “The Fed’s shift to average inflation targeting means that it will allow inflation to overshoot its 2% target for periods of time before raising rates, in order to make up for past undershoots,” he explained. With this in mind, despite all the recent stimulus injected into the U.S. economy, Eitelman said any rate hikes are unlikely to occur until 2022 at the earliest.
AstraZeneca vaccine trial hits roadblock. Are markets worried?
Shifting to the race to develop a vaccine for COVID-19, Eitelman noted that AstraZeneca (NYSE:AZN) announced a pause on late-stage trial testing for its experimental vaccine after a participant in the UK suffered a serious illness. With testing paused, the company probably won’t report the results from its trials until closer to the end of the year, he said. Because AstraZeneca had been one of the companies near the front of the pack in the race for a vaccine, the delay in testing is a bit of a disappointment for investors eager to see the economy return to a more normalized state, Eitelman explained. However, he noted that pausing a vaccine trial for these reasons is actually more the norm than the exception.
Additionally, other companies working on a vaccine for COVID-19, such as Moderna (NASDAQ:MRNA) and Pfizer (NYSE:PFE), are still on track to report results from their Phase 3 trials in October or November, Eitelman said. “Ultimately, while the news around AstraZeneca is a setback, it doesn’t derail our economic or financial market outlook moving forward,” he concluded.
These views are subject to change at any time based upon market or other conditions and are current as of the date at the top of the page.
Investing involves risk and principal loss is possible.
Past performance does not guarantee future performance.
Forecasting represents predictions of market prices and/or volume patterns utilizing varying analytical data. It is not representative of a projection of the stock market, or of any specific investment.
This material is not an offer, solicitation or recommendation to purchase any security. Nothing contained in this material is intended to constitute legal, tax, securities or investment advice, nor an opinion regarding the appropriateness of any investment, nor a solicitation of any type.
The general information contained in this publication should not be acted upon without obtaining specific legal, tax and investment advice from a licensed professional. The information, analysis and opinions expressed herein are for general information only and are not intended to provide specific advice or recommendations for any individual entity.
Please remember that all investments carry some level of risk. Although steps can be taken to help reduce risk it cannot be completely removed. They do no not typically grow at an even rate of return and may experience negative growth. As with any type of portfolio structuring, attempting to reduce risk and increase return could, at certain times, unintentionally reduce returns.
Investments that are allocated across multiple types of securities may be exposed to a variety of risks based on the asset classes, investment styles, market sectors, and size of companies preferred by the investment managers. Investors should consider how the combined risks impact their total investment portfolio and understand that different risks can lead to varying financial consequences, including loss of principal. Please see a prospectus for further details.
Indexes are unmanaged and cannot be invested in directly.
The S&P 500® Index, or the Standard & Poor’s 500, is a stock market index based on the market capitalizations of 500 large companies having common stock listed on the NYSE or NASDAQ.
The Nasdaq Composite Index is the market capitalization-weighted index of over 2,500 common equities listed on the Nasdaq stock exchange.
Copyright © Russell Investments Group LLC 2020. All rights reserved.
This material is proprietary and may not be reproduced, transferred, or distributed in any form without prior written permission from Russell Investments. It is delivered on an “as is” basis without warranty.